Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2020, vol. 29, nr 4, April, p. 449–452

doi: 10.17219/acem/115004

Publication type: original article

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

The effect of diabetes on vitreous levels of adiponectin and inflammatory cytokines in experimental rat model

Yusuf Özay1,A,B, Dilay Ozek2,A, Filiz Yıldırım3,A,B,C,D,E,F, Zuhal Yıldırım4,A,B,C,D,E,F

1 Department of Medical Biology, Faculty of Medicine, Adiyaman University, Turkey

2 Second Ophthalmology Clinic, Ankara Numune Education and Research Hospital, Turkey

3 Clinic of Internal Medicine, Polatlı Duatepe Government Hospital, Ankara, Turkey

4 Etimesgut Public Health Laboratory, Ankara, Turkey

Abstract

Background. Diabetic retinopathy is one of the most common eye diseases faced by diabetic patients. It is a slow-progressing complication that results from damage to the blood vessels of the retina.
Objectives. To investigate the role of adiponectin and inflammatory cytokines in the vitreous of diabetic rats.
Material and Methods. The study was conducted in 3–4-month-old male albino Wistar rats (180–240 g). The animals were divided into 2 groups (n = 40 in each group): the diabetes group and the control group. A single dose of streptozotocin (STZ) (45 mg/kg) in citrate buffer (0.1 M; pH 4.5) was intraperitoneally (ip.) injected into the diabetes group rats. A single dose of citrate buffer was injected ip. into the control group rats. All subjects were sacrificed under intramuscular (im.) Na-thiopental (50 mg/kg) anesthesia. The rats’ eyelids were opened with an eye speculum and vitreous samples were collected with 20G needles 4 mm posterior to the limbus. The levels of vitreous adiponectin, tumor necrosis factor α (TNF-α), interferon γ (INF-γ), and matrix metalloproteinase (MMP)-2 and -9 were determined using a solid-phase sandwich enzyme-linked immunosorbent assay (ELISA).
Results. The levels of adiponectin, TNF-α, INF-γ, MMP-2, and MMP-9 in the rat vitreous were significantly higher in the diabetes group than in the control group (p < 0.05).
Conclusion. Elevated adiponectin, TNF-α, and INF-γ levels in the vitreous may be diagnostically useful in diabetic retinopathy, and inflammatory cytokines in the vitreous may be pathogenically important in this concentration.

Key words

inflammation, diabetes mellitus, adiponectin, vitreous

References (37)

  1. Frank RN. Diabetic retinopathy. N Engl J Med. 2004;350:48–58.
  2. Klein R, Klein BEK, Jensen SC, Moss SE. The relation of socineconomic factors to the incidence of proliferative diabetic retinopathy and loss of vision. Ophthalmology. 1994;101:68–76.
  3. Chew EY. Epidemiology of diabetic retinopathy. Hosp Med. 2003;64:396–399.
  4. Stehower CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes progressive, interrelated, and independently associated with risk of death. Diabetes. 2002;51:1157–1165.
  5. Cicik E, Tekin H, Akar S, et al. Interleukin-8 nitric oxide and glutathione status in proliferative vitreoretinopathy and proliferative diabetic retinopathy. Ophthalmic Res. 2003;35:251–255.
  6. Kim SJ, Kim S, Park J, et al. Differential expression of vitreous proteins in proliferative diabetic retinopathy. Curr Eye Res. 2006;31:231–240.
  7. Hernandez C, Segura RM, Fonollosa A, Carrasco E, Francisco, Simo R. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med. 2005;22:719–722.
  8. Vinores SA, Derevjanik NI, Mahlow J, Berkowitz BA, Wilson CA. Electron microscopic evidence for the mechanism of blood retinal barrier breakdown in diabetic rabbits: Comparison with magnetic resonance imaging. Pathol Res Pract. 1998;194:497–505.
  9. Esposito K, Pantilo A, Di-Palio C. Effects of weight loss and life style changes on vascular inflammatory marers in obese women. J Am Med Assoc. 2003;289:1799–1804.
  10. Pankowska E, Szaleck M. Adiponectin as an adipose tissue hormone and its role in the metabolic syndrome and cardiovascular disease. Endokrynol Diabetol Chor. 2005;11(3):187–190.
  11. Aygun C, Senturk D, Hulogu S, Uraz S, Celebi A. Serum levels of hepatoprotective adiponectin in non alcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2006;18(2):175–180.
  12. Nicholas SB, Mauer M, Basgen JM, Aguiniga E, Chon Y. Effect of angiotensin II on glomerular structure in streptozotsin-induced diabetics rats. Am J Nephrol. 2004;24(5):549–556.
  13. Chang YC, Wu WC. Dyslipidemia and diabetic retinopathy. Rev Diabet Stud. 2013;10:121–132.
  14. Barot M, Gokulgandhi MR, Mitra AK. Mitochondrial dysfunction in retinal disease. Curr Eye Res. 2011;36:1069–1077.
  15. Lian K, Du C, Liu Y, et al. Impaired adiponectin signaling contributes to disturbed catabolism of branched-chain amino acids in diabetic mice. Diabetes. 2015;64:49–59.
  16. Zietz B, Buechier K, Kobuch K, Neumeier M, Scholmenrich A, Schaffer A. Serum levels of adiponectin are associated with diabetic retinopathy and with adiponectin gene mutations in Caucasian patients with diabetes mellitus type 2. Exp Clin Endocrinol Diabetes. 2008;116(9):532–536.
  17. Kawana J, Arora R. The role of adiponectin in obesity, diabetes and cardiovascular disease. J Cardiometab Syndr. 2009;4:44–49.
  18. Shen YY, Peake PW, Charlesworth JA. Review article: Adiponectin: Its role in kidney disease. Nephroloy (Carlton). 2008;13:528–534.
  19. Yilmaz MI, Sonmez A, Acikel C, et al. Adiponectin may play apart in the pathogenesis of diabetic retinopathy. Eur J Endocrinol. 2004;151(1):135–140.
  20. Misu H, Ishikura K, Kurita S, et al. Inverse correlation between serum levels of selenoprotein P and adiponectin in patients with type 2 diabetes. PLoS One. 2012;7(4):34952–34959.
  21. Costagliola C, Daniele A, dell’Omo R, et al. Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection. Exp Eye Res. 2013;110:50–54.
  22. Mao D, Peng H, Li Q, et al. Aqueous humor and plasma adiponectin levels in proliferative diabetic retinopathy patients. Curr Eye Research. 2012;37:803–808.
  23. Hong SB, Lee JJ, Kim SH, et al. The effects of adiponectin and inflammatory cytokines on diabetic vascular complications in obese and non-obese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2016;111:58–65.
  24. Kato K, Osawa H, Ochi M, et al. Serum total and high molecular weight adiponectin levels are correlated with the severity of diabetic retinopathy and neuropathy. Clin Endocrinol. 2008;68(3):442–449.
  25. Danna M, Peng H, Qiuhong L, et al. Aqueous humor and plasma adiponectin levels in proliferative diabetic retinopathys patients. Current Eye Res. 2012;37(9):803–808.
  26. Feigold KR, Grunfeld C. Role of cytokines in inducing hyperlipidemia. Diabetes. 1992;41:97–101.
  27. Wemer S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev. 2003;83:835–870.
  28. Shen H, Yao P, Lee E, Greenhalgh D, Soulika AM. Interferon-gamma inhibits healing post scald burn injury. Wound Repair Regen. 2012;20:580–591.
  29. Costagliola C, Romano V, De Tollis M, et al. TNF-alpha levels in tears: A novel biomarker to assess the degree of diabetic retinopathy. Mediators Inflamm. 2013;2013:629529–629535.
  30. Koskela UE, Kuusisto SM, Nissinen AE, Savolainen MJ, Liinamaa MJ. High vitreous concentration of IL-6 and IL-8, but not of adhesion molecules in relation to plasma concentrations in proliferative diabetic retinopathy. Ophthalmic Res. 2013;49:108–114.
  31. Kowluru RA, Zhong Q, Santos JM. Matrix metalloproteinases in diabetic retinopathy: Potential role of MMP-9. Expert Opin Investig Drugs. 2012;21(6):797–805.
  32. De La Pazz MA, Itoh Y, Toth CA, Nagesa H. Matrix metalloproteinases and their inhibitors in human vitreous. Invest Ophthalmol Vis Sci. 1998;39:1256–1260.
  33. Kosano H, Okano T, Katsura Y, et al. ProMMP-9 (92 kDa gelatinase) in vitreous fluid of patients with proliferative diabetic retinopathy. Life Sci. 1999;64:2307–2315.
  34. Jin M, Kashiwagi K, Lizuka Y, Tanaka Y, Imai M, Tsukahara S. Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina. 2001;21:28–33.
  35. Noda K, Ishida S, Inoue M, et al. Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2003;44(5):2163–2170.
  36. Giebel SJ, Menicucci G, McGuire PG, Das A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest. 2005;85:567–607.
  37. Das A, Mandal M, Chakraborti T, Mandal A, Chakraborti S. Isolation of MMP-2 from MMP-2/TIMP-2 complex: Characterization of the complex and the free enzyme in pulmonary vascular smooth muscle plasma membrane. Biochim Biophys Acta. 2004;1674:158–174.
© Wroclaw Medical University